The aim of this prospective single-centre phase II study is to investigate the therapeutic
efficacy and safety of cetuximab in combination with Gemcitabine and Oxaliplatin (GEMOX) in
the palliative first line treatment of biliary tract cancer (BTC) patients.
Phase:
Phase 2
Details
Lead Sponsor:
Association of Research on the Biology of Liver Tumors